Digestive Diseases Centre Gastro SIA

At Digestive Diseases Centre Gastro SIA in Riga, clinical research is focused on digestive system diseases, with studies centered on improving care for chronic gastrointestinal conditions. The main goal is to evaluate new therapies, compare treatment options, and strengthen understanding of how these diseases respond to targeted care.

• Studies in ulcerative colitis, including moderate to severe active forms and left-sided disease, to assess treatment effectiveness and safety.
• Research in Crohn’s disease aimed at testing targeted therapies for better disease control.
• Trials in gastroparesis to evaluate treatments for delayed stomach emptying and related symptoms.

The site is also involved in work on biosimilar and comparative treatment strategies, helping determine whether newer options can match or improve established standards of care.

This research program includes multiple studies in inflammatory bowel disease, especially ulcerative colitis and Crohn’s disease. The trials are designed to examine how well emerging therapies can induce remission, reduce symptoms, and support longer-term disease management.

• Testing targeted therapies for moderate to severe Crohn’s disease and ulcerative colitis.
• Evaluating the safety and efficacy of newer biologic treatments for active disease.
• Comparing investigational options with established therapies to guide better treatment choices.

Several studies at Digestive Diseases Centre Gastro SIA focus on patients who have not yet responded to targeted therapy, reflecting a strong emphasis on practical treatment improvement.

A major share of the site’s clinical trials addresses ulcerative colitis, covering patients with moderate to severe active disease as well as those with milder left-sided involvement. These studies aim to improve symptom control, support remission, and evaluate both safety and effectiveness across different treatment approaches.

• Assessing new therapies for moderately to severely active ulcerative colitis.
• Comparing investigational medicines with standard treatments to understand relative benefit.
• Studying long-term outcomes and tolerability in people living with UC.

The research at this Riga site also includes work on biosimilars and advanced biologic agents, showing a broad commitment to expanding options for people with chronic bowel inflammation.

Another area of interest is gastroparesis, a condition that affects stomach emptying and can cause ongoing digestive discomfort. The trials in this field are focused on easing symptoms and determining whether new treatment options can improve daily functioning for affected patients.

• Evaluating therapies for idiopathic gastroparesis and diabetic gastroparesis.
• Studying whether investigational treatments can improve signs and symptoms of delayed stomach emptying.
• Exploring better approaches to symptom management in chronic digestive disorders.

These studies complement the broader inflammatory bowel disease work at Digestive Diseases Centre Gastro SIA, highlighting a diverse but clearly focused gastroenterology research portfolio.